BusinessDermira Announces Proposed Offering of $250 Million of Convertible Senior NotesBy Nasdaq OMXMay 9, 2017, 8:05 PM UTC
BusinessDermira Reports First Quarter 2017 Financial Results and Provides Corporate UpdateBy Nasdaq OMXMay 8, 2017, 8:09 PM UTC
BusinessDermira to Present at Needham 16th Annual Healthcare ConferenceBy Nasdaq OMXMar 28, 2017, 8:05 PM UTC
BusinessDermira Presents New Data Highlighting Patient Outcomes in Axillary Hyperhidrosis at Maui Derm MeetingBy Nasdaq OMXMar 21, 2017, 11:30 AM UTC
BusinessDermira to Highlight Data for Three Clinical Programs at Annual Maui Derm MeetingBy Nasdaq OMXMar 17, 2017, 12:30 PM UTC
BusinessDermira Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional SharesBy Nasdaq OMXMar 7, 2017, 9:05 PM UTC
BusinessNew CIMZIA® (certolizumab pegol) data in moderate-to-severe plaque psoriasis and psoriatic arthritis presented at American Academy of Dermatology 2017 Annual MeetingBy Nasdaq OMXMar 4, 2017, 2:00 PM UTC
BusinessDermira Presents New Data in Primary Axillary Hyperhidrosis and Acne at American Academy of Dermatology 2017 Annual MeetingBy Nasdaq OMXMar 3, 2017, 1:24 PM UTC
